Publications by authors named "Lewis C Cantley"

Are you Lewis C Cantley?   Register this Author


Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma.
Bioorg Med Chem Lett 2018 Apr 27. Epub 2018 Apr 27.
California Institute for Biomedical Research, 11119 North Torrey Pines Road, La Jolla, CA 92037, USA; Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. Electronic address:


Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling.
Cell 2017 Dec 16;171(7):1545-1558.e18. Epub 2017 Nov 16.
Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA; Department of Pharmacology, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:


PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.
Mol Cell 2017 Mar;65(6):999-1013.e7
Signalling and Cancer Metabolism Team, Division of Cancer Biology, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK; Division of Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK. Electronic address:

α-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH).
J Med Chem 2017 Feb 27;60(4):1591-1597. Epub 2017 Jan 27.
Medicinal Chemistry Research Group (CMFA), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain , 73 avenue Mounier, B-1200 Brussels, Belgium.





Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.
Cell 2016 Jan;164(3):433-46
Division of Hematology and Oncology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School (HMS), Boston, MA 02215, USA. Electronic address:



PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Mol Oncol 2015 Oct 16;9(8):1694-703. Epub 2015 May 16.
Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.

Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet.
Biochim Biophys Acta 2015 Oct 11;1852(10 Pt A):2056-65. Epub 2015 Jul 11.
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer.
Nat Med 2015 May 13;21(5):457-66. Epub 2015 Apr 13.
1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.

Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain.
Cancer Res 2015 Feb 15;75(3):554-65. Epub 2014 Dec 15.
Department of Biochemistry and Biology, College of Natural Science and Mathematics, University of Houston, Houston, Texas.

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Nature 2014 Oct 10;514(7524):628-32. Epub 2014 Aug 10.
1] Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis.
Cell 2014 Sep;158(6):1309-1323
Center for Regenerative Medicine and Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Electronic address:

Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
Cancer Discov 2014 Aug 27;4(8):896-904. Epub 2014 May 27.
Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine; Divisions of

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
J Clin Oncol 2014 Apr 24;32(12):1202-9. Epub 2014 Mar 24.
Ingrid A. Mayer, Vandana G. Abramson, Justin M. Balko, María Gabriela Kuba, Melinda E. Sanders, and Carlos L. Arteaga, Vanderbilt University, Nashville, TN; Steven J. Isakoff, Massachusetts General Hospital, Boston, MA; Andres Forero, University of Alabama, Birmingham, AL; Jeffrey T. Yap, Huntsman Cancer Institute, Salt Lake City, UT; Annick D. Van den Abbeele and Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Yisheng Li, MD Anderson Cancer Center, Houston, TX; and Lewis C. Cantley, Weill Cornell Medical College, New York, NY.

A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Cancer Res 2014 Jan 9;74(1):15-23. Epub 2013 Dec 9.
Authors' Affiliations: Department of Cancer Biology; Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute; Departments of Biological Chemistry and Molecular Pharmacology and Systems Biology; Rodent Histopathology Core, DF/HCC, Harvard Medical School; Department of Surgery, Brigham and Women's Hospital; Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston; Novartis Institutes for Biomedical Research, Cambridge, Massacheusetts; Department of System Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and Novartis Institutes for Biomedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland.

What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
Cancer Discov 2013 Dec 21;3(12):1345-54. Epub 2013 Nov 21.
1Division of Hematology-Oncology, University of California Irvine Medical Center, Orange, California; 2Division of Signal Transduction, Beth Israel Deaconess Medical Center; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and 4Department of Medicine, Weill Cornell Medical College, New York, New York.

Lin28 enhances tissue repair by reprogramming cellular metabolism.
Cell 2013 Nov;155(4):778-92
Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Boston, MA 02115, USA; Manton Center for Orphan Disease Research, Boston, MA 02115, USA; Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Medicine, Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.

Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.
Cell 2013 Nov;155(4):844-57
Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA; Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.

Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.
Mol Cell 2013 Oct 3;52(2):161-72. Epub 2013 Oct 3.
Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA; Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA; Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.


Fetal deficiency of lin28 programs life-long aberrations in growth and glucose metabolism.
Stem Cells 2013 Aug;31(8):1563-73
Stem Cell Transplantation Program, Stem Cell Program, Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Boston, Massachusetts, USA.




MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling.
Cell 2013 Jul 3;154(2):311-324. Epub 2013 Jul 3.
Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.




Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.
Nature 2013 Apr 27;496(7443):101-5. Epub 2013 Mar 27.
Division of Genomic Stability and DNA Repair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.



Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.
Cancer Metab 2015 12;3:12. Epub 2015 Oct 12.
Department of Pharmacology, University of Texas Southwestern Medical Center, 6001 Forest Park Drive, Dallas, 75390-8807 TX USA ; Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX USA.

Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system.
Proc Natl Acad Sci U S A 2016 07 16;113(27):7596-601. Epub 2016 Jun 16.
Meyer Cancer Center, Weill Cornell Medical College, New York, NY 10065; Department of Medicine, Weill Cornell Medical College, New York, NY 10065;

Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Proc Natl Acad Sci U S A 2016 07 8;113(30):E4338-47. Epub 2016 Jul 8.
Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215;

Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.
Proc Natl Acad Sci U S A 2016 08 15;113(35):9810-5. Epub 2016 Aug 15.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115;






OF